Allergy

The intranasal epinephrine spray is being developed for use with Intravail, a nasal absorption enhancing technology.

The EPIT skin patch is still seeking indication as the first peanut allergy desensitization therapy to reach the market.

A new survey study found that less than half of food allergies reported by adults have actually been diagnosed by a physician.

Children often develop food allergies prior to developing asthma, and the former condition is associated with a greater risk of the latter condition in later life.

Rapidly accumulating evidence indicates that delayed introduction of allergenic foods may have contributed to the unexplained rise in food allergy rates over the past 20 years.

Asthma is the most common chronic disease of childhood. Cellphones might help improve its management.

The biologic AR101 was previously shown to significantly desensitize peanut allergies in a pediatric and adolescent patient population.

Results may ease concerns for many physicians and patients who live in colder climates.

A 48-year-old man presents with severe atopic dermatitis that he’s had since childhood. Can allergy shots succeed where standard treatments failed?

The AR101 oral therapy—a biologic designed to desensitize peanut allergies, manufactured by Aimmune Therapeutics—is anticipated to be submitted for FDA approval in the next month.